ConcertAI's TeraRecon and 3DR Labs Announce Expanded Partnership to Transform the Delivery of AI-Enabled Image Post Processing Clinical Services for US Healthcare Providers
ConcertAI's TeraRecon, a leader in integrating advanced imaging workflows with clinical AI, has announced an expanded partnership with 3DR ® Labs, a leading provider of 3D medical image post-processing and clinically integrated AI services in the United States. This collaboration aims to enhance clinical service delivery for advanced imaging by expanding the range of domain-specific workflows and clinical AI technologies. As a result, it will benefit numerous hospitals across the country.
The foundation of this partnership is TeraRecon's new TRSubscription™ offering, which grants 3DR Labs access to a comprehensive suite of advanced visualization tools, AI-powered clinical applications, and cloud services, all under a unified model. By integrating clinical AI and cloud technologies, both companies aim to equip healthcare providers with the latest innovations in imaging diagnostics and surgical planning. Additionally, TeraRecon will become a founding member of 3DR's AI Labs, a vendor-agnostic services platform designed for universal workflow integration using AI.
'Our partnership with 3DR addresses critical industry challenges, including increased pressure on hospital resources, rising demand for complex imaging analysis services, and the need for practical AI applications with validated clinical benefits,' said Dhiraj Carumbaya, SVP & GM for ConcertAI's TeraRecon business. 'Our new technology subscription gives customers full access to a range of clinical applications to comprehensively deliver exceptional service across their imaging enterprise.'
The partnership will help transition 3DR's clinical operations to the Cloud, an integral component of the TRSubscription™. This migration will streamline the interaction between 3DR Labs and its hospital clients by enabling secure, cloud-based data transmission and remote visualization capabilities, enhancing 3DR Labs' ability to scale its services while maintaining the highest clinical quality and data security standards.
'As demand for advanced medical imaging analysis continues to grow, this partnership allows 3DR Labs to stay at the forefront of innovation,' said Mike Jackman, CEO of 3DR Labs. 'High-quality, outsourced 3D medical imaging services and AI-enabled insights enhance our ability to serve our hospital partners efficiently. By leveraging TeraRecon's technology and partnering to offer AI as-a-service, we can scale our operations to meet increasing clinical needs while maintaining our commitment to exceptional quality and service.'
TeraRecon's new TRSubscription™ introduces cutting-edge advancements in AI for image processing technologies and clinical workflows throughout the imaging enterprise. This solution enables 3DR Labs to reinforce its leadership in offering clinical services for medical imaging post-processing and innovative surgical planning for hospitals. Visit TeraRecon at ACC2025, booth 17009, to learn more.
About ConcertAI
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified ® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
About 3DR Labs
Headquartered in Louisville, Kentucky, 3DR Labs, LLC provides round-the-clock access to more than 250 expert radiologic technologists, cutting-edge imaging software, and advanced clinical AI workflow solutions. 3DR's AI Labs, a vendor-agnostic services platform, connects imaging departments to a gateway of 3D workflow automation, delivering quality, speed, and efficiency within medical imaging systems. Founded in 2005, 3DR Labs provides services to over a thousand hospital imaging departments, stand-alone imaging centers, and radiology practices. Turnaround times for CT and MRI exams are guaranteed within hours or even minutes. For more information, please visit https://3drlabs.com/.
SOURCE: ConcertAI
Copyright Business Wire 2025.
PUB: 03/29/2025 07:00 AM/DISC: 03/29/2025 07:00 AM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
THYME&TABLE™ LAUNCHES PREMIER LINE OF KITCHEN APPLIANCES, MADE EXCLUSIVELY FOR WALMART
Pushing boundaries of aesthetics and function with kitchen electronics, Thyme&Table™ achieves unprecedented price points with innovative design and efficient manufacturing. NEW YORK, June 9, 2025 /PRNewswire/ -- Thyme&Table™, a family-owned leader in stylish, high-performance homewares at affordable prices, today announced the launch of its first line of premier kitchen appliances – the perfect balance between functionality and home aesthetic. Designed and manufactured exclusively for Walmart, the new coffee, blender and heating kitchen electronics are easy to use and priced for amazing value, like the two-mode Single-Serve Blender for $59, a 6QT Air Fryer for $79 or a Mini Espresso Machine for $128. And the sleek, modern designs will enhance any kitchen's look and elevate everyday culinary moments. For years, Thyme&Table™, a Walmart-exclusive brand offered by Core Home, has been celebrated for its incredible deals on dinnerware, cookware and bakeware sets, like the 12-Piece stoneware tableware collection. Now it's pushing the boundaries of aesthetics and function with kitchen electronics, achieving unprecedented price points through efficient and ethical manufacturing and innovative design. "We're proud to partner with Walmart to bring this exclusive line to customers across the country and can't wait for you to experience it for yourself," said Core Home CEO, parent company of Thyme&Table™, Steven Bram. "This collection marks an exciting new chapter for our brand. Each piece has been thoughtfully designed with the same attention to detail, craftsmanship, and aesthetic excellence that defines all Thyme&Table™ products," Bram said. "From powerful performance to sleek finishes, these appliances don't just work seamlessly — they look sleek and elevated on your countertop, too. We've reimagined what luxury can look like in the kitchen — accessible, refined, and always reliable." Said Danielle Lyman, VP Cooking & Dining Merchandising, Walmart U.S., "At Walmart, we're proud to offer customers quality, on-trend home products at incredible prices so creating the space of their dreams is always within reach. Our new Walmart-exclusive Thyme&Table™ appliances were thoughtfully designed with performance and style in mind, and our customers will be delighted by what they'll discover, at prices we know they'll love." INTRODUCING THE KITCHEN APPLIANCESIn select U.S.-based Walmart stores and Supercenters and online at Thyme&Table™ is expanding its brand showcase with: Blenders Countertop Blender Duo, $79. The Thyme&Table™ Blender Duo offers extraordinary versatility for every recipe. This dynamic set includes a powerhouse duo of blending options for large-batch or single-serve prep compatible with a single base. Trust our Smart Crush™ technology to efficiently slice, dice & crush, while the vortex blending pulls down ingredients for continuous & consistent blending. Single-Serve Blender, $59. The Thyme&Table™ Single-Serve Blender offers seamless precision & powerful vortex blending for masterfully crafted smoothies, milkshakes, salsas, nut butters & more. With two simple & straightforward modes, this compact blender makes meal prep & healthy habits easier than ever. Easily flip & switch from the 6-point stainless steel blade system to the Smart Seal™ lid with a reusable straw for sipping on the go. Coffee Barista Grade Espresso Machine, $368. Craft barista-quality brews at home with the Thyme&Table™ all-in-1 Grind & Brew Espresso Machine. This efficient machine allows optimum customization & control for coffee lovers with 30 grind dial settings from coarse to fine, solo & doppio brewing options, & adjustable grind & shot times. Use the built-in steam wand to froth milk for homemade lattes, cappuccinos & more. Barista Mini Espresso Machine, $128. Craft rich, full-bodied espresso with the Thyme&Table™ Mini Espresso Machine, featuring a 15-bar pressure system and 52mm portafilter. The 1-hole steam wand effortlessly creates silky micro-foam, perfect for lattes & cappuccinos. Tailor each shot with solo and doppio filter baskets, & enjoy a preheated cup in just 60 seconds for a seamless brewing experience. Drip Coffee Maker, $79. Elevate your coffee experience with the Thyme&Table™ 12-cup programmable Drip Coffee Maker featuring an XL shower head spout that fully extracts flavor from your grounds. Enjoy programmable brewing options, an Over Ice mode & adjustable cup sizes for a personalized brew. Conical Burr Coffee Grinder, $59. Achieve barista-quality coffee grounds with the Thyme&Table™ Conical Burr Coffee Grinder, offering 32 grind settings to create your ideal batch. Choose between pre-programmed volume or manual options via the intuitive one-touch panel while the large 772g capacity hopper allows for less refilling, more grinding. To dispense, select either the included 100g grounds container with lid to store or the attachable portafilter bracket to brew. Multi-Capsule Machine, $109. Experience seamless brewing with the Thyme&Table™ Multi-Capsule Machine, featuring intelligent capsule matching. Simply insert your desired drawer & the machine will detect the right way to brew with corresponding presets. Customize your brewing by selecting the volume & moving the adjustable drip tray. The compact, versatile design is ideal for efficient brewing, especially in small spaces. Heating 6QT Air Fryer, $79. The Thyme&Table™ 6 QT Air Fryer is ideal for creating equally guilt-free & delicious meals or snacks in minutes. Its unique design features a CrispFlow™ basket, with a vortex design for enhanced air circulation & ThymeCrisp™ heating for the perfect golden crisp. Choose from 5 heating modes, 5 presets, or adjustable time & temperature settings to craft customized recipes. 6QT Slow Cooker, $59. Discover endless cooking possibilities with the Thyme&Table™ 6 QT Slow Cooker. Its intuitive, user-forward design features a non-stick ceramic serving pot, tempered glass lid with silicone rim, & lid holder to prevent kitchen messes. 2-Slice Toaster, $39. The Thyme&Table™ 2-slice, self-adjusting Toaster is engineered with precise ThymeToast technology for stream-lined, intuitive use. Turn the dial to select your ideal shade, from 1-7. Select the Bagel preset & turn your slices cut-side out to toast. The removable slide-out crumb tray ensures quick cleaning & the extra-lift lever makes it easy to access smaller slices. About Thyme&Table™ Thyme&Table™ is part of New York City-based Core Home, a leading manufacturer of innovative and trend-forward home products. With a commitment to creating functional, stylish, and accessible solutions, Core Home has become a trusted name in the industry, collaborating with top brands to deliver exceptional collections. View original content to download multimedia: SOURCE Core Home
Yahoo
21 minutes ago
- Yahoo
U.S. FDA Approves Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
ENFLONSIA is a preventive monoclonal antibody designed to protect infants against a spectrum of RSV disease severity, including worsening disease requiring hospitalization ENFLONSIA is the first and only RSV preventive option administered to infants using the same dose regardless of weight RAHWAY, N.J., June 09, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season. ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection through 5 months, a typical RSV season, with the same 105 mg dose regardless of weight. A typical RSV season usually spans autumn to spring of the next year. "RSV disease is the leading cause of infant hospitalization in the U.S. and can lead to serious respiratory conditions like bronchiolitis and pneumonia," said Dr. Octavio Ramilo, chair of the Department of Infectious Diseases at St. Jude Children's Research Hospital and investigator for the CLEVER (MK-1654-004) and SMART (MK-1654-007) trials. "ENFLONSIA combines dosing convenience with strong clinical data showing significant reductions in RSV disease incidence and hospitalizations, making it a promising new intervention to help protect infants from RSV." ENFLONSIA should not be administered to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA. See additional Selected Safety Information below. The approval is based on results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) evaluating a single dose of ENFLONSIA administered to preterm and full-term infants (birth to 1 year of age). The trial met its primary and key secondary endpoints, as outlined below. ENFLONSIA demonstrated a reduction in incidence of RSV-associated medically attended lower respiratory infections (MALRI) requiring ≥1 indicator of lower respiratory infection (LRI) or severity compared to placebo through 5 months (primary endpoint) by 60.5% (95% CI: 44.2, 72.0, p<0.001) (incidence rates: ENFLONSIA, 0.026; placebo, 0.065). ENFLONSIA demonstrated a reduction in RSV-associated hospitalizations through 5 months (key secondary endpoint) by 84.3% (95% CI: 66.7, 92.6, p<0.001) (incidence rates: ENFLONSIA, 0.004; placebo, 0.024), showing increasing efficacy with increasing disease severity. The approval is also supported by results from the Phase 3 SMART trial (MK-1654-007) evaluating the safety and efficacy of ENFLONSIA versus palivizumab in infants at increased risk for severe RSV disease. "ENFLONSIA provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season with the same dose regardless of weight," said Dr. Dean Y. Li, president, Merck Research Laboratories. "We are committed to ensuring availability of ENFLONSIA in the U.S. before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems." The U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of ENFLONSIA in infants. Ordering is anticipated to begin in July, with shipments delivered before the start of the 2025-2026 RSV season. About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA (clesrovimab-cfor) is Merck's extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants who are born during or entering their first RSV season. ENFLONSIA is administered using non-weight-based dosing and is designed to provide direct, rapid and durable protection through 5 months, a typical RSV season. For infants born during the RSV season, ENFLONSIA is to be administered starting from birth. For infants born outside of the RSV season, ENFLONSIA should be administered prior to the start of their first RSV season. For infants undergoing cardiac surgery with cardiopulmonary bypass during or entering their first RSV season, an additional 105 mg dose is recommended as soon as the infant is stable after surgery. Selected Safety Information for ENFLONSIA (clesrovimab-cfor) Do not administer ENFLONSIA to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA. Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy. The most common adverse reactions were injection-site erythema (3.8%), injection-site swelling (2.7%) and rash (2.3%). About Clinical Trials and Data Supporting U.S. FDA Approval The CLEVER trial (MK-1654-004) (NCT04767373) was a Phase 2b/3, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ENFLONSIA in early and moderate preterm infants (≥29 to <35 weeks gestational age [GA]) and late preterm and full-term infants (≥35 weeks GA) entering their first RSV season. Participants were randomized 2:1 to receive a single 105 mg dose of ENFLONSIA (N=2,411) or saline placebo (N=1,203) by intramuscular (IM) injection. The primary endpoint was the incidence of participants with RSV-associated medically attended lower respiratory infection (MALRI) characterized as cough or difficulty breathing and requiring ≥1 indicator of LRI (wheezing, rales/crackles) or severity (chest wall in-drawing/retractions, hypoxemia, tachypnea, dehydration due to respiratory symptoms) from Day 1 through Day 150 (5 months) after dosing. Medically attended includes all health care provider visits in settings such as outpatient clinic, clinical study site, emergency department, urgent care center and/or hospital. The key secondary endpoint was RSV-associated hospitalization through Day 150 (5 months). The trial demonstrated that the safety profile of ENFLONSIA in infants entering their first RSV season was generally comparable to placebo. The most common adverse reactions were injection-site erythema occurring within 5 days post-dose (ENFLONSIA: 3.8%; placebo: 3.3%), injection-site swelling occurring within 5 days post-dose (ENFLONSIA: 2.7%; placebo: 2.6%) and rash occurring within 14 days post-dose (ENFLONSIA: 2.3%; placebo: 1.9%). Participants were monitored for serious adverse events (SAEs) through the duration of their participation for up to 365 days post-dose. Most (≥97%) of the adverse reactions were toxicity grade 1 (mild) or grade 2 (moderate). The SMART trial (MK-1654-007) (NCT04938830) was a Phase 3, randomized, partially-blind, palivizumab-controlled, multi-site trial to evaluate the safety and efficacy of ENFLONSIA in infants at increased risk of severe RSV disease, including early (<29 weeks GA) or moderate preterm infants (≥29 to ≤35 weeks GA) and infants with chronic lung disease of prematurity or congenital heart disease of any GA. Participants were randomized 1:1 to receive ENFLONSIA (N=446) or palivizumab (N=450) by IM injection. Among infants at increased risk of severe RSV disease and entering their first RSV season, the trial demonstrated that the safety profile of ENFLONSIA was generally comparable to palivizumab and consistent with the safety profile of ENFLONSIA in infants in the CLEVER trial. The efficacy of ENFLONSIA in infants at increased risk for severe RSV disease was established by extrapolation of efficacy of ENFLONSIA from the CLEVER trial to the SMART trial based on similar pharmacokinetic exposure. The incidence rates of RSV-associated MALRI requiring ≥1 indicator of LRI or severity and RSV-associated hospitalization were generally comparable between ENFLONSIA (3.6%, 95% CI: 2.0, 6.0 and 1.3%, 95% CI: 0.4, 2.9, respectively) and palivizumab (2.9%, 95% CI: 1.5, 5.2 and 1.5%, 95% CI: 0.5, 3.2, respectively) through Day 150 (5 months). In clinical trials, when ENFLONSIA was given concomitantly with routine childhood vaccines, the safety profile of the co-administered regimen was generally comparable to the safety profile when ENFLONSIA and childhood vaccines were administered alone. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( Please see Prescribing Information for ENFLONSIA (clesrovimab-cfor) at and Patient Information/Medication Guide for ENFLONSIA at View source version on Contacts Media Contacts:Julie Cunningham(617) 519-6264Brittany Redmer(215) 527-6922 Investor Contacts:Damini Chokshi(732) 594-1577Peter Dannenbaum(732) 594-1579 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
AlidaBio Launches First Service Provider Partnership with Baylor College of Medicine's GARP Core to Offer Multiplexed RNA Modification Sequencing
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Alida Biosciences, a leader in next-generation RNA modification analysis, is proud to announce its first official service provider: the Genomic and RNA Profiling (GARP) Core at Baylor College of Medicine. This new service offering is powered by AlidaBio's EpiPlex™ Platform, the first and only solution that concurrently detects and quantifies multiple RNA modifications alongside gene expression using short-read sequencing. Officially launched in February 2025, the platform combines the EpiPlex RNA Library Prep Kit with the EpiScout™ Analysis Suite, delivering a complete, single-workflow solution to uncover the functional impact of RNA modifications in development, aging, and disease. Researchers interested in accessing this service can contact the core directly at garpcore@ "We're thrilled to see our first service provider come online at a world-class institution like Baylor College of Medicine," said Dr. Gudrun Stengel, CEO of AlidaBio. "GARP's deep expertise in transcriptomic profiling, combined with our pioneering RNA modification technology, ensures that researchers across disciplines can access this breakthrough capability through an experienced and trusted partner." "This technology represents a significant leap forward in RNA biology," said Dr. Daniel Kraushaar, Director of the GARP Core. "With the ability to simultaneously assess gene expression and multiple RNA modifications, researchers can now gain unprecedented insight into post-transcriptional regulation. We're excited to offer this cutting-edge platform to the Baylor research community and beyond." Designed for clinical and translational research, the EpiPlex Kit is optimized for samples with limited RNA input. With sensitivity down to 50 ng of total RNA, the assay can deliver high-resolution results from challenging materials like tissue biopsies or FFPE samples—where RNA tends to be fragmented and of lower quality. . The accompanying EpiScout Analysis Suite is an intuitive, informatics platform that automates analysis and visualization of complex epitranscriptomic data. By integrating multiple RNA modifications with expression data, researchers gain a multidimensional view of transcriptome regulation without the usual bioinformatics bottlenecks. The EpiPlex assay is automatable and streamlined for efficiency, enabling completion of the wet-lab portion of the workflow in a single day. It is available in 8- and 24-sample formats, supporting labs of any size. Early-access partners across academia and industry have validated the platform's accuracy, reproducibility, and potential for collaborative, large-scale studies. AlidaBio continues to expand the EpiPlex platform, with future plans including additional modification targets, higher base resolution, and targeted panels tailored for drug discovery and disease-specific applications. For more information about AlidaBio's products and services, please visit About Alida BiosciencesFounded in 2020, Alida Biosciences is transforming epigenomics with powerful, user-friendly tools for RNA modification analysis. Our technologies enable concurrent detection and quantification of multiple RNA modifications from clinically relevant samples, supporting breakthroughs in research, therapeutics, and diagnostics. AlidaBio is backed by Genoa Ventures, FusionX Ventures, General Inception and Vertical Venture Partners, and supported by SBIR grants from the NHGRI. Media Contact Nikita Warnernwarner@ View original content to download multimedia: SOURCE Alida Biosciences Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
